FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2078512377> ?p ?o ?g. }

• W2078512377 endingPage "1112" @default.
• W2078512377 startingPage "1112" @default.
• W2078512377 abstract "Until the middle of the 20th century, little knowledge of the behaviour of prostate cancer existed and awareness of its exquisite sensitivity to hormones had not been realised. The conventional understanding was that prostate cancer was an autonomous, self-perpetuating, and fatal malignant disease, the progression of which could not be changed by external manipulation. In 1941, Charles Brenton Huggins, a Canadian-born American surgeon, revolutionised our understanding of prostate cancer and irrevocably changed the approach of physicians in managing and researching the treatment of neoplastic disease in general. His pioneering work heralded the era of rational drug therapy for all cancers and earned Huggins the Nobel Prize in Physiology and Medicine in 1966. Charles Huggins graduated from Harvard Medical School (Boston, MA, USA) in 1924. In 1927, he was appointed to the surgical faculty at the University of Chicago (Chicago, IL, USA) where he became Professor of Surgery in 1936. Subsequently, in 1966, he became the second surgeon to win a Nobel Prize in Medicine, with a comment from the Nobel Committee proclaiming Huggins’ work had “already given many years of an active and useful life to patients with advanced cancer over the entire civilized world—patients who would have been lost to other forms of therapy”. Many have suggested that his ground-breaking discoveries, fi rst published in 1941, should have been acknowledged by the committee at a much earlier date. In the original study by Huggins and Hodges (his student), eight patients with metastatic disease to bone were selected from an initial group of 47 patients with prostate cancer. All eight patients underwent bilateral orchidectomy; however, before this procedure, fi ve were started on daily injections of stilboestrol or oestradiol benzoate, and three were injected with daily testosterone propionate. Serum acid-phosphatase concentrations decreased in patients who received oestrogen injection before the procedure and increased in those who received testosterone propionate. From these fi ndings, Huggins and Hodges concluded that prostate cancer was receptive to androgenic activity in the body and that metastatic prostate cancer was inhibited by eliminating circulating androgens—either by surgical orchidectomy or by administration of oestrogens. Moreover, they also showed that prostate cancer was activated by androgen injections. These fi ndings have provided the scientifi c basis for the contemporary treatment of prostate cancer. For nearly 30 years after this seminal report by Huggins and Hodges, patients with advanced prostatic carcinoma were managed either by surgical orchidectomy or oestrogens, until it was shown that treatment with oestrogens resulted in substantial thromboembolic and cardiovascular complications. This fi nding stimulated further research into alternative hormonal treatments, which culminated in the development of various antiandrogens (eg, cyproterone acetate and fl utamide) and most notably synthetic luteinising-hormonereleasing-hormone (LHRH) agonists in the 1970s. The therapeutic eff ectiveness of LHRH in achieving medical castration has yet to be surpassed. Although these hormonal treatments were originally used to manage patients with metastatic disease, androgen ablation therapy is now used in a neoadjuvant or adjuvant setting in combination with surgery or radiation in patients with locally advanced disease only or in those with biochemical relapse after radical treatment for localised disease. The epic work by Huggins and Hodges will remain a cornerstone in the annals of medical literature because it initiated the use of endocrine therapy in the management of disseminated prostate cancer and showed that the course of neoplastic disease could be changed by rational external intervention. One can state with certainty that there are few articles in science, which have had, or will have, such a lasting impact." @default.
• W2078512377 created "2016-06-24" @default.
• W2078512377 creator A5034378600 @default.
• W2078512377 creator A5072038658 @default.
• W2078512377 creator A5083172675 @default.
• W2078512377 creator A5085595832 @default.
• W2078512377 date "2008-11-01" @default.
• W2078512377 modified "2023-09-27" @default.
• W2078512377 title "Hormone therapy: a revolution in understanding prostate cancer" @default.
• W2078512377 cites W2108955823 @default.
• W2078512377 doi "https://doi.org/10.1016/s1470-2045(08)70282-1" @default.
• W2078512377 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/19012861" @default.
• W2078512377 hasPublicationYear "2008" @default.
• W2078512377 type Work @default.
• W2078512377 sameAs 2078512377 @default.
• W2078512377 citedByCount "4" @default.
• W2078512377 countsByYear W20785123772022 @default.
• W2078512377 crossrefType "journal-article" @default.
• W2078512377 hasAuthorship W2078512377A5034378600 @default.
• W2078512377 hasAuthorship W2078512377A5072038658 @default.
• W2078512377 hasAuthorship W2078512377A5083172675 @default.
• W2078512377 hasAuthorship W2078512377A5085595832 @default.
• W2078512377 hasConcept C121608353 @default.
• W2078512377 hasConcept C126322002 @default.
• W2078512377 hasConcept C143998085 @default.
• W2078512377 hasConcept C17744445 @default.
• W2078512377 hasConcept C199539241 @default.
• W2078512377 hasConcept C2779473830 @default.
• W2078512377 hasConcept C2780192828 @default.
• W2078512377 hasConcept C2780275930 @default.
• W2078512377 hasConcept C530470458 @default.
• W2078512377 hasConcept C71924100 @default.
• W2078512377 hasConceptScore W2078512377C121608353 @default.
• W2078512377 hasConceptScore W2078512377C126322002 @default.
• W2078512377 hasConceptScore W2078512377C143998085 @default.
• W2078512377 hasConceptScore W2078512377C17744445 @default.
• W2078512377 hasConceptScore W2078512377C199539241 @default.
• W2078512377 hasConceptScore W2078512377C2779473830 @default.
• W2078512377 hasConceptScore W2078512377C2780192828 @default.
• W2078512377 hasConceptScore W2078512377C2780275930 @default.
• W2078512377 hasConceptScore W2078512377C530470458 @default.
• W2078512377 hasConceptScore W2078512377C71924100 @default.
• W2078512377 hasIssue "11" @default.
• W2078512377 hasLocation W20785123771 @default.
• W2078512377 hasLocation W20785123772 @default.
• W2078512377 hasOpenAccess W2078512377 @default.
• W2078512377 hasPrimaryLocation W20785123771 @default.
• W2078512377 hasRelatedWork W1984525398 @default.
• W2078512377 hasRelatedWork W2068562160 @default.
• W2078512377 hasRelatedWork W2414715318 @default.
• W2078512377 hasRelatedWork W2724151471 @default.
• W2078512377 hasRelatedWork W2791072685 @default.
• W2078512377 hasRelatedWork W2912565296 @default.
• W2078512377 hasRelatedWork W2913942481 @default.
• W2078512377 hasRelatedWork W2996796527 @default.
• W2078512377 hasRelatedWork W3005883651 @default.
• W2078512377 hasRelatedWork W4294967918 @default.
• W2078512377 hasVolume "9" @default.
• W2078512377 isParatext "false" @default.
• W2078512377 isRetracted "false" @default.
• W2078512377 magId "2078512377" @default.
• W2078512377 workType "article" @default.